{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T22:35:47Z","timestamp":1726439747826},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,3,14]],"date-time":"2014-03-14T00:00:00Z","timestamp":1394755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s11684-014-0319-1","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T02:34:52Z","timestamp":1395110092000},"page":"254-258","source":"Crossref","is-referenced-by-count":2,"title":["Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock"],"prefix":"10.1007","volume":"8","author":[{"given":"Muhammad","family":"Furqan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yamei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akintunde","family":"Akinleye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Sarungbam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Gass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Seiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,14]]},"reference":[{"issue":"7","key":"319_CR1","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/00000478-199207000-00001","volume":"16","author":"PM Banks","year":"1992","unstructured":"Banks PM, Chan J, Cleary ML, Delsol G, Wolf-Peeters CD, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Mason D, Pileri S, Ralfikiaer E, Stein H, Warnke RA. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992; 16(7): 637\u2013640","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"319_CR2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.1993.11.4.802","volume":"11","author":"RA Shivdasani","year":"1993","unstructured":"Shivdasani RA, Hess JL, Skarin AT, Pinkus GS. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin\u2019s lymphoma. J Clin Oncol 1993; 11(4): 802\u2013111","journal-title":"J Clin Oncol"},{"issue":"2","key":"319_CR3","first-page":"115","volume":"36","author":"E Campo","year":"1999","unstructured":"Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36(2): 115\u2013127","journal-title":"Semin Hematol"},{"issue":"11","key":"319_CR4","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"J Armitage","year":"1997","unstructured":"Armitage J. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 1997; 89(11): 3909\u20133918","journal-title":"Blood"},{"issue":"10","key":"319_CR5","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood.V87.10.4358.bloodjournal87104358","volume":"87","author":"S Pittaluga","year":"1996","unstructured":"Pittaluga S, Bijnens L, Teodorovic I, Hagenbeek A, Meerwaldt JH, Somers R, Thomas J, Noordijk EM, De Wolf-Peeters C. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood 1996; 87(10): 4358\u20134367","journal-title":"Blood"},{"issue":"6","key":"319_CR6","first-page":"879","volume":"17","author":"J Kauh","year":"2003","unstructured":"Kauh J, Baidas SM, Ozdemirli M, Cheson BD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park, NY) 2003; 17(6): 879\u2013891, 896; discussion 896\u2013898","journal-title":"Oncology (Williston Park, NY)"},{"issue":"4","key":"319_CR7","first-page":"797","volume":"13","author":"R Bigoni","year":"1996","unstructured":"Bigoni R, Negrini M, Veronese ML, Cuneo A, Castoldi GL, Croce CM. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996; 13(4): 797\u2013802","journal-title":"Oncogene"},{"issue":"6","key":"319_CR8","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","volume":"89","author":"LH Argatoff","year":"1997","unstructured":"Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89(6): 2067\u20132078","journal-title":"Blood"},{"issue":"8","key":"319_CR9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F, Callet-Bauchu E, Felman P, Berger F, Salles G, Coiffier B. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12(8): 1281\u20131287","journal-title":"Leukemia"},{"issue":"2","key":"319_CR10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2141.2007.06526.x","volume":"137","author":"N Parry-Jones","year":"2007","unstructured":"Parry-Jones N, Matutes E, Morilla R, Brito-Babapulle V, Wotherspoon A, Swansbury GJ, Catovsky D. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol 2007; 137(2): 117\u2013124","journal-title":"Br J Haematol"},{"issue":"4","key":"319_CR11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5858\/2008-132-565-EL","volume":"132","author":"JA Ferry","year":"2008","unstructured":"Ferry JA. Extranodal lymphoma. Arch Pathol Lab Med 2008; 132(4): 565\u2013578","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"319_CR12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/cncr.27898","volume":"119","author":"AJ Ambinder","year":"2013","unstructured":"Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer 2013; 119(8): 1570\u20131577","journal-title":"Cancer"},{"issue":"4","key":"319_CR13","first-page":"312","volume":"83","author":"M Bertini","year":"1998","unstructured":"Bertini M, Rus C, Freilone R, Botto B, Calvi R, Novero D, Orsucci L, Vitolo U, Palestro G, Resegotti L. Mantle cell lymphoma: a retrospective study on 27 patients. Clinical features and natural history. Haematologica 1998; 83(4): 312\u2013316","journal-title":"Haematologica"},{"issue":"11","key":"319_CR14","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","volume":"15","author":"M Bernard","year":"2001","unstructured":"Bernard M, Gressin R, Lefr\u00e8re F, Dr\u00e9nou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia 2001; 15(11): 1785\u20131791","journal-title":"Leukemia"},{"issue":"1","key":"319_CR15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","volume":"19","author":"A Ferrer","year":"2008","unstructured":"Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Guti\u00e9rrez G, Mercadal S, Campo E, Rozman C, L\u00f3pez-Guillermo A, Montserrat E. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008; 19(1): 135\u2013141","journal-title":"Ann Oncol"},{"issue":"32","key":"319_CR16","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1200\/JCO.2009.23.9731","volume":"27","author":"HE Eve","year":"2009","unstructured":"Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009; 27(32): e189\u2013e190, author reply e191","journal-title":"J Clin Oncol"},{"issue":"8","key":"319_CR17","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, Elstrom R, Niesvizky R, Ely S, Diliberto M, Melnick A, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27(8): 1209\u20131213","journal-title":"J Clin Oncol"},{"issue":"10","key":"319_CR18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, L\u00e9ger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005; 16(10): 1675\u20131682","journal-title":"Ann Oncol"},{"issue":"4","key":"319_CR19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SFH, Cogliatti S, Bertoni F, Waltzer U, Fey MF, Betticher DC, Schefer H, Pichert G, Stahel R, Ketterer N, Bargetzi M, Cerny T; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23(4): 705\u2013711","journal-title":"J Clin Oncol"},{"issue":"9","key":"319_CR20","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99(9): 706\u2013714","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"319_CR21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1756-8722-5-64","volume":"5","author":"S Cang","year":"2012","unstructured":"Cang S, Mukhi N, Wang K, Liu D. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol 2012; 5(1): 64","journal-title":"J Hematol Oncol"},{"issue":"1","key":"319_CR22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1(1): 36","journal-title":"Exp Hematol Oncol"},{"issue":"2Suppl6","key":"319_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/sonc.2002.32749","volume":"29","author":"B Coiffier","year":"2002","unstructured":"Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin\u2019s lymphoma. Semin Oncol 2002; 29(2 Suppl 6): 18\u201322","journal-title":"Semin Oncol"},{"issue":"1","key":"319_CR24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1475-2867-12-38","volume":"12","author":"J Zhao","year":"2012","unstructured":"Zhao J, Xu Z, Liu D, Lu Q. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int 2012; 12(1): 38","journal-title":"Cancer Cell Int"},{"issue":"8","key":"319_CR25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","volume":"114","author":"M Ghielmini","year":"2009","unstructured":"Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114(8): 1469\u20131476","journal-title":"Blood"},{"issue":"9873","key":"319_CR26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W; Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381(9873): 1203\u20131210","journal-title":"Lancet"},{"issue":"9873","key":"319_CR27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(12)61965-5","volume":"381","author":"CA Jacobson","year":"2013","unstructured":"Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013; 381(9873): 1163\u20131165","journal-title":"Lancet"},{"issue":"1","key":"319_CR28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1756-8722-5-55","volume":"5","author":"K Lu","year":"2012","unstructured":"Lu K, Wang X. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol 2012; 5(1): 55","journal-title":"J Hematol Oncol"},{"key":"319_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013; 6:27","journal-title":"J Hematol Oncol"},{"key":"319_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-6-36","volume":"6","author":"M Wu","year":"2013","unstructured":"Wu M, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol 2013;6:36","journal-title":"J Hematol Oncol"},{"key":"319_CR31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-8722-6-40","volume":"6","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Huang H, Wei G. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol 2013;6:40","journal-title":"J Hematol Oncol"},{"issue":"6","key":"319_CR32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369(6): 507\u2013516","journal-title":"N Engl J Med"},{"issue":"1","key":"319_CR33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O\u2019Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369(1): 32\u201342","journal-title":"N Engl J Med"},{"key":"319_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-6-59","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Chen Y, Mukhi N, Song Y, Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013; 6:59","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-014-0319-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11684-014-0319-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-014-0319-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T02:31:11Z","timestamp":1648607471000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11684-014-0319-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,14]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s11684-014-0319-1","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,14]]}}}